Reviewing Teleflex (TFX) and Its Competitors

Teleflex (NYSE:TFX) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its rivals? We will compare Teleflex to related businesses based on the strength of its earnings, dividends, profitability, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Teleflex and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Teleflex	-39.67%	11.93%	5.44%
Teleflex Competitors	-278.23%	-150.07%	-21.87%

Volatility & Risk

Teleflex has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Teleflex’s rivals have a beta of 2.49, meaning that their average stock price is 149% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Teleflex and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teleflex	1	5	5	1	2.50
Teleflex Competitors	4251	10479	18202	824	2.46

Teleflex presently has a consensus price target of $154.40, indicating a potential upside of 10.37%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 25.86%. Given Teleflex’s rivals higher possible upside, analysts clearly believe Teleflex has less favorable growth aspects than its rivals.

Dividends

Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 1.0%. Teleflex pays out -5.8% of its earnings in the form of a dividend. As a group, “Healthcare Equipment & Supplies” companies pay a dividend yield of 2.2% and pay out 53.8% of their earnings in the form of a dividend.

Insider & Institutional Ownership

95.6% of Teleflex shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 0.7% of Teleflex shares are owned by company insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Teleflex and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Teleflex	$2.25 billion	-$905.64 million	-6.01
Teleflex Competitors	$1.89 billion	$137.23 million	10.70

Teleflex has higher revenue, but lower earnings than its rivals. Teleflex is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Teleflex beats its rivals on 8 of the 15 factors compared.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.